NA
PRME icon

NewEdge Advisors’s Prime Medicine PRME Stock Holding History

NewEdge Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69K Hold
1,000
– – ﹤0.01% 3800
2026
Q1 		$3.48K Hold
1,000
– – ﹤0.01% 3681
2025
Q4 		$3.47K Hold
1,000
– – ﹤0.01% 3770
2025
Q3 		$5.54K Buy
+1,000
New +$4.06K ﹤0.01% 3501

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

NewEdge Advisors's PRME Position: Q2 2026 in Review

NewEdge Advisors held its Prime Medicine (PRME) position steady in Q2 2026 at 1,000 shares worth $3.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3800.

NewEdge Advisors first reported a position in PRME in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.54K in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • NewEdge Advisors held 1,000 shares of Prime Medicine worth $3.69K as of Q2 2026.
  • NewEdge Advisors left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3800 holding.
  • NewEdge Advisors first reported a position in Prime Medicine in Q3 2025 and has held it in 4 quarters since.
  • NewEdge Advisors's Prime Medicine position peaked at $5.54K in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.